Jun 2026 (Q2 FY26) — Aug 5, 2026
Innoviz Technologies Q2 FY26 — Record Revenue Driven by Defense Entry and Automotive Progress
Read the full callInnoviz Technologies earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 12.7 | Quarterly, as filed | Quarter to Dec 2025 | Revenue from operations as filed. No quarter a year earlier is in the series, so no change is shown. | |
| Operating margin | -165.1 | Operating profit / revenue | Quarter to Dec 2025 | For the quarter; a change is in percentage points. No quarter a year earlier is in the series, so no change is shown. | |
| Net profit | -21.3 | Quarterly, as filed | Quarter to Dec 2025 | Profit after tax as filed. No quarter a year earlier is in the series, so no change is shown. |
Price
1Y: $2.38 on 14 Oct 2025 → $0.28. High $2.38 (14 Oct 2025), low $0.28 (14 Oct 2026).
Overview
Call summaries
Innoviz Technologies Q2 FY26 — Record Revenue Driven by Defense Entry and Automotive Progress
Read the full callEvery analysed call
Financials
| Line item | Dec 2025 |
|---|---|
| Sales | 13 |
| Operating profit | -21 |
| Operating margin | −165.1% |
| Profit before tax | -21 |
| Tax rate | −0.3% |
| Net profit | -21 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -150 | -231 | -385 | -512 | -635 | -730 | -798 |
| Total liabilities | — | 270 | 296 | 28 | 63 | 66 | 53 | 61 |
| Fixed assets | — | 11 | 13 | 15 | 30 | 26 | 23 | 20 |
| Investments | — | — | 0 | 12 | 42 | 13 | 12 | 9 |
| Total assets | — | 124 | 73 | 327 | 255 | 219 | 132 | 138 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -39 | -69 | -62 | -83 | -93 | -93 | -77 | -48 |
| Cash from investing | 40 | -41 | 30 | -282 | 125 | 1 | 75 | -21 |
| Cash from financing | 1 | 163 | 9 | 337 | 1 | 62 | 0 | 51 |
| Net cash flow | 1 | 54 | -23 | -26 | 31 | -30 | -1 | -17 |
| Capital expenditure | -7 | -6 | -5 | -4 | -23 | -7 | -4 | -4 |
| Free cash flow | -46 | -75 | -67 | -86 | -116 | -100 | -81 | -52 |
15 filings between Apr 30, 2026 and Aug 4, 2026.
Nobody bought or sold INVZ on the open market in this window. The filings below are 13 awards and 2 other filings.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 4, 2026 | Moscovici Avishay Ben Chief R&D Officer | Award | 66,336 | $0 |
| Aug 4, 2026 | Hofstetter Elad Ben Chief Business Officer | Award | 54,112 | $0 |
| Aug 4, 2026 | Cegla Eldar Mordechay Chief Financial Officer | Award | 73,184 | $0 |
| Aug 4, 2026 | Luski Ido Chief Operating Officer | Award | 64,688 | $0 |
| Aug 4, 2026 | Har Even Yoav Director | Award | 90,162 | $0 |
| Jul 7, 2026 | Keilaf Omer David Chief Executive Officer | Other | 679,400 | $0 |
| May 13, 2026 | Aharon Aharon Director | Award | 110,668 | $0 |
| May 13, 2026 | Von Witzleben Alexander Reymar Karl-Wilhelm Director | Award | 110,668 | $0 |
| May 13, 2026 | Steimberg Amichai Director | Award | 265,602 | $0 |
| May 13, 2026 | Falk Dan Michael Director | Award | 110,668 | $0 |
| May 13, 2026 | Sheridan James J. III Director | Award | 110,668 | $0 |
| May 13, 2026 | Stav Orit Director | Award | 110,668 | $0 |
| May 13, 2026 | Maor Shenaar Ronit Director | Award | 110,668 | $0 |
| May 13, 2026 | Jacoby Stefan Director | Award | 110,668 | $0 |
| Apr 30, 2026 | Keilaf Omer David Chief Executive Officer | Other | 723,019 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow Innoviz Technologies Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading